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2 Interleukin)17A (IL)17A) promotes the osteoclast (OC))like differentiation of dendritic cells (DCs) in multiple myeloma (MM), and contributes to the pathogenesis of myeloma bone disease (MBD). In our study, EVR significantly abrogated the in vitro OC)like activity of DCs from 12 MM patients.
Exploring the EVR effects, we found that the inhibition of the osteo)erosive activity of OC)DCs was mostly due to the blockade of signals driven by the IL)17A receptor toward CEBPbeta/MAFB axis Therefore, MM patients with MBD would probably benefit from mTOR inhibition.
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The development of myeloma bone disease (MBD) stems from the osteoclast (OC) hyperactivity promoted by malignant plasma cells. In this context, immature DCs (iDCs) may transdifferentiate within myeloma bone marrow into functional OC)like cells according to their monocytoid derivation (1, 2) and the effect of the abundance of interleukin (IL))1, IL)6, IL)11 as well as both IL)17A and RANK)L (receptor activator of nuclear factor kappa)B ligand) (3, 4).
In the bone marrow of multiple myeloma (MM) patients, T)helper (Th))17 cells release variable amounts of IL)17A whose levels are of great effort for the formation of lytic lesions (5)8). In fact, this cytokine drives the differentiation of OC progenitors by enhancing the release of a number of osteoclastogenic factors such as monocyte chemoattractant protein (MCP))1, macrophage inflammatory protein (MIP))1, matrix metalloprotease)9 (MMP)9) and adhesion molecules (9, 10).
Finally, IL)17A promotes the fusion of DCs, resulting in the multinucleated bone resorbing giant cells in Langherans histiocytosis while enhances the sensitivity of OC precursors to RANK)L (11, 12) IL)17A stimulates with high affinity the IL)17RA that drives the OC)like transdifferentiation of iDCs through the CEBPB (CCAAT/enhancer)binding protein beta) factor, thus leading the transcription of NFATc1 (nuclear factor of activated T)cells, cytoplasmic))1, MITF (microphthalmia) associated transcription factor) and cFos while modulates MAFB (musculoaponeurotic fibrosarcoma oncogene homolog B) as the negative regulator of OC maturation (14, 15) . In addition, IL)17A regulates the OC polarization and bone remodelling priming the CEBPB expression for the balance of Lip/Lap isoforms while restrains experimental and human osteoclastogenesis by MAFB up)regulation (14) . CEBPB controls the proliferation and differentiation of OCs as well as of other cell types through the alternative translation)initiation at distinct in frame start sites of Lap and Lip isoforms ( "). The production of Lap and Lip isoforms is also regulated by signals under the control of the mammalian M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 target of rapamycin (mTOR) pathway ( ). In addition, rapamycin selectively inhibits the OC generation and proliferation in wild)type mice while those from CEBPB gene)deleted strains are apparently not affected and also show altered MAFB transcription ( #).
Since the mTOR cascade is activated in bone resorbing OCs, its inhibition by rapamycin results, through the over)expression of Lap over Lip isoform, in defective osteoclastogenesis of giant cell tumor and osteoporotic murine model. (19, 20) . It is noteworthy that MAFB is also deregulated in MM while IL)6 and other marrow growth factors activate the PI3K/AKT/mTOR pathway to promote MM cell survival, migration and drug resistance (21)23 ' The Mann)Whitney test was applied to calculate the differences in erosive pits, areas of erosion and RNA values. The one)way Anova test was used to calculate the effect of different concentrations of EVR on DC viability and adhesion to the bone substrates. ). On the contrary, the bone erosion behaviour of OC)
DCs was greatly restrained in a dose)dependent fashion following the treatment with EVR. As shown in Figure 1C and in representative panels in Figure 1D , both the formation of pits (69.6+6% vs. Our experiments showed that EVR had practically no effect on viability of both iDCs and OC)DCs as well as on proliferation and adhesion to bone substrates, thus suggesting that osteoclastogenesis impairment mostly depends on the interference with the MAFB/CEBPB signaling. Moreover, osteoclast activity it is not correlated to the impaired production within microenvironment of pro) osteoclastogenic factors by tumor cells, as described in other cancer models (28, 29) . Indeed, we
showed that the effect of EVR on osteoclastogenesis by OC)DCs is mostly related to the Lip/CEBPB down)regulation in parallel to both the Lap isoform and MAFB activation. Therefore, the up)regulation by EVR of these transcription factors in OC)DCs definitely reflects the increased suppression of the OC)like activity through NFATc1 and cFos modulation (30).
Previous studies described that the OC)like properties of OC)DCs are coupled with an up) regulation of OC genes (27) 
